874290-59-2

Basic information

• Product Name: CarbaMic acid, (4-borono-3-fluorophenyl)-, C-(phenylMethyl) ester (9CI)
• Synonyms: CarbaMic acid, (4-borono-3-fluorophenyl)-, C-(phenylMethyl) ester (9CI);N-CBZ-4-AMINO-2-FLUOROPHENYLBORONIC ACID;(4-borono-3-fluorophenyl)-, C-(phenylMethyl) ester;4-(benzyloxycarbonyl)-2-fluorophenylboronicacid;(4-Borono-3-fluorophenyl)carbamic acid C-(phenylmethyl) ester;(2-fluoro-4-phenylmethoxycarbonylphenyl)boronic acid;N-(benzyloxycarbonyl)-2-fluorophenylboronic acid
• CAS NO: 874290-59-2
• Molecular Formula: C₁₄H₁₃BFNO₄
• Molecular Weight: 274.0520832
• Mol File: 874290-59-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• Solubility: Dichloromethane; Ethanol
• PKA: 8.43±0.58(Predicted)
• CAS DataBase Reference: CarbaMic acid, (4-borono-3-fluorophenyl)-, C-(phenylMethyl) ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, (4-borono-3-fluorophenyl)-, C-(phenylMethyl) ester (9CI)(874290-59-2)
• EPA Substance Registry System: CarbaMic acid, (4-borono-3-fluorophenyl)-, C-(phenylMethyl) ester (9CI)(874290-59-2)

Safety Data

• Hazardous Substances Data: 874290-59-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CarbaMic acid, (4-borono-3-fluorophenyl)-, C-(phenylMethyl) ester (9CI) is used as a key intermediate in the synthesis of Tedizolid-d3 (T013752), an antibacterial drug. CarbaMic acid, (4-borono-3-fluorophenyl)-, C-(phenylMethyl) ester (9CI) contributes to the development of new and effective treatments for bacterial infections, addressing the growing need for novel antibiotics to combat drug-resistant bacteria.
As an intermediate in the synthesis of Tedizolid-d3, CarbaMic acid, (4-borono-3-fluorophenyl)-, C-(phenylMethyl) ester (9CI) plays a significant role in the pharmaceutical industry, enabling the production of innovative and potentially life-saving medications. Its application in the development of TR-700 highlights the importance of chemical research and synthesis in advancing medical treatments and addressing global health challenges.

Upstream product

• 5419-55-6 Triisopropyl borate 
• 510729-01-8 (4-bromo-3-fluorophenyl)carbamic acid benzyl ester 
• 7732-18-5 water 

Downstream Products

• 1220910-89-3 3-fluoro-4-(6-(2-methyl-2H-tetrazole-5-yl)pyridin-3-yl)phenyl-carbamic acid benzylester 
• 856866-72-3 (5R)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridra-3-yl]phenyl}-5-(hydroxymethyl)-1,3-oxazoiidin-2-one 
• 1835340-19-6 (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridine-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate 

Relevant articles and documents

Preparation method of tedizolid phosphate and intermediate thereof

The invention discloses a preparation method of tedizolid phosphate and an intermediate thereof. The preparation method of a tedizolid phosphate intermediate II comprises the following steps: 1, in anorganic solvent, under a condition of presence of a catalyst and zinc powder, performing a reaction on 3-fluorine-4-bromophenyl amino benzyl formate so as to obtain a solution of a tedizolid phosphate intermediate III; and 2, in an organic solvent, under a condition of presence of a palladium catalyst and a base, performing a coupling reaction on the solution of the tedizolid phosphate intermediate III obtained in the step 1 with 2-methyl-5-(5-bromopyridine-2-yl) tetrazole, so as to obtain the tedizolid phosphate intermediate II. The preparation method disclosed by the invention is free of toxic reagent, mild in reaction condition, safe to operate, environmentally friendly, high in yield, high in prepared product purity and low in production cost. Tedizolid phosphate prepared from the tedizolid phosphate intermediate II disclosed by the invention is high in yield, high in purity, capable of meeting raw material medicine standards and applicable to industrial production.

Novel synthesis method for key intermediate of tedizolid

The invention relates to a novel synthesis method for a key intermediate of tedizolid. The method is characterized in that a starting material SM is dissolved in an anhydrous solvent; then a Grignard reagent isopropyl magnesium halide is added to prepare a Grignard reagent of SM; then n-butyllithium is added to prepare a SM magnesium-lithium complex; and then the SM magnesium-lithium complex is reacted with borate to prepare the target intermediate. The method provided by the invention overcomes the problem of extremely low reaction temperature in the prior art, greatly improves reaction yield, and is easy to realize industrialized production.

METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM

Methods of preparing a class of oxazolidinones useful to impede bacterial growth are disclosed.